ID   NCC-GCTB4-C1
AC   CVCL_B3VJ
DR   Wikidata; Q110433084
RX   PubMed=34731453;
WW   https://en.cellline.jp/product/ncc-gctb4-c1/
CC   Part of: NCC sarcoma cell line panel.
CC   Population: Japanese.
CC   Senescence: It is possible that this cell line is not immortal and has a finite life span (personal communication of Kondo T.).
CC   Doubling time: 65.78 hours (PubMed=34731453).
CC   Sequence variation: Mutation; HGNC; 4764; H3-3A; Simple; p.Gly35Trp (c.103G>T) (G34W); Zygosity=Heterozygous (PubMed=34731453).
CC   Derived from site: In situ; Bone, left proximal tibia; UBERON=UBERON_0008772.
ST   Source(s): PubMed=34731453
ST   Amelogenin: X,Y
ST   CSF1PO: 12,13
ST   D13S317: 8,12
ST   D16S539: 9,11
ST   D21S11: 28.2,30
ST   D5S818: 12
ST   D7S820: 10,11
ST   TH01: 6,9
ST   TPOX: 8
ST   vWA: 17,18
DI   NCIt; C4304; Malignancy in giant cell tumor of bone
DI   ORDO; Orphanet_363976; Giant cell tumor of bone
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   52Y
CA   Cancer cell line
DT   Created: 16-12-21; Last updated: 30-01-24; Version: 5
//
RX   PubMed=34731453; DOI=10.1007/s13577-021-00639-4;
RA   Ono T., Noguchi R., Yoshimatsu Y., Tsuchiya R., Sin Y., Nakagawa R.,
RA   Hirabayashi K., Ozawa I., Kikuta K., Kondo T.;
RT   "Establishment and characterization of the NCC-GCTB4-C1 cell line: a
RT   novel patient-derived cell line from giant cell tumor of bone.";
RL   Hum. Cell 35:392-399(2022).
//